Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) [Phase 3]

View source ↗

Summary

Phase 3 trial of pembrolizumab in platinum-pretreated recurrent/metastatic nasopharyngeal cancer completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma
• Nasopharyngeal Neoplasms

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Nasopharyngeal Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2021-12-15